Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

Inflammatory Bowel Disease I: Introduction

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiovascular risk profiles in patients with primary sclerosing cholangitis.

European journal of gastroenterology & hepatology·2026

Same author

Zeitschrift fur Gastroenterologie·2024

Same author

Zeitschrift fur Gastroenterologie·2023

Same author

Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2023

Same author

Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.

Alimentary pharmacology & therapeutics·2023

Same author

Platelet-Rich stroma from Crohn's disease patients for treatment of perianal fistula shows a higher myeloid cell profile compared to non-IBD controls.

Stem cell research·2023

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Review article: defining remission in ulcerative colitis.

S P L Travis¹, P D R Higgins, T Orchard

¹Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. simon.travis@ndm.ox.ac.uk

Alimentary Pharmacology & Therapeutics

|May 28, 2011

Summary

This summary is machine-generated.

Defining remission in ulcerative colitis is crucial for consistent patient outcomes. A proposed standard uses clinical symptoms and endoscopy, with histopathology offering prognostic value for better treatment goals.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Related Experiment Videos

Last Updated: Jun 1, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Area of Science:

Gastroenterology
Clinical Medicine
Inflammatory Bowel Disease Research

Background:

Lack of international consensus on ulcerative colitis (UC) disease activity scoring systems.
Absence of a validated definition for ulcerative colitis remission.
Varied approaches to measuring UC severity hinder comparative research.

Purpose of the Study:

To review principles and components for defining UC remission.
To propose a standardized definition for UC remission.
To improve patient outcomes through a clear remission definition.

Main Methods:

Literature review of remission standards in clinical trials, guidelines, and practice.
Analysis of components, utility, and treatment strategies for UC remission definitions.
Consideration of patient perspectives on remission.

Main Results:

Discrepancies in remission definitions complicate trial comparisons and outcome assessments.
Mucosal healing, assessed by endoscopy and histopathology, is increasingly linked to remission duration.
Patient-defined remission may correlate with endoscopic findings but not necessarily remission duration.

Conclusions:

A proposed standard for UC remission integrates clinical symptoms and endoscopy.
Histopathology represents a third dimension of remission with potential prognostic value.
A unified definition of remission is essential for predicting long-term outcomes and guiding treatment goals in ulcerative colitis.